Ocugen Inc Equity-NMS: OCGN

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$1.03

Open :

$1.02

Today's high :

$1.04

Today's low :

$1.01

52W low :

$0.515

52W high :

$1.29

EPS(TTM): :

-0.19

Shares O/S :

312.3 M

Market cap :

321.67 M

What is the share price of Ocugen Inc today?

Ocugen Inc (OCGN) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Ocugen Inc?

Yes, Indian Investors can invest in the Ocugen Inc (OCGN) Share by opening an international trading account with Angel One.

How can I purchase Ocugen Inc shares in India?

Purchasing Ocugen Inc (OCGN) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Ocugen Inc (OCGN) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Ocugen Inc?

Yes, you can purchase fractional shares of Ocugen Inc (OCGN) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Ocugen Inc?

The market capitalization of Ocugen Inc on January 1, 1970, is $0.

What documents are required to invest in Ocugen Inc stocks?

In order to invest in Ocugen Inc (OCGN) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.